CWG
ACRS icon

C WorldWide Group’s Aclaris Therapeutics ACRS Stock Holding History

C WorldWide Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-148,506
Closed -$890K – 85
2019
Q1 		$890K Sell
148,506
-4,448
-3% -$29.5K 0.01% 107
2018
Q4 		$1.13M Sell
152,954
-52,797
-26% -$544K 0.02% 98
2018
Q3 		$2.99M Sell
205,751
-36,500
-15% -$626K 0.04% 84
2018
Q2 		$4.84M Buy
242,251
+166,986
+222% +$3.09M 0.07% 67
2018
Q1 		$1.32M Sell
75,265
-13,335
-15% -$283K 0.02% 94
2017
Q4 		$2.19M Sell
88,600
-7,700
-8% -$188K 0.03% 81
2017
Q3 		$2.49M Sell
96,300
-300
-0.3% -$8.04K 0.04% 88
2017
Q2 		$2.62M Buy
96,600
+15,100
+19% +$411K 0.04% 87
2017
Q1 		$2.43M Buy
+81,500
New +$2.35M 0.04% 82

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

C WorldWide Group's ACRS Position: Q2 2019 in Review

C WorldWide Group sold out of Aclaris Therapeutics (ACRS) in Q2 2019, closing a stake of 148,506 shares — an estimated $890K sold.

C WorldWide Group first reported a position in ACRS in Q1 2017 and held it in 9 quarters. The position peaked at $4.84M in Q2 2018. 84 funds tracked by Wall St. Rank hold ACRS as of Q2 2019.

  • C WorldWide Group reported no remaining Aclaris Therapeutics position as of Q2 2019 after selling out during the quarter.
  • C WorldWide Group sold 148,506 Aclaris Therapeutics shares in Q2 2019, an estimated $890K.
  • C WorldWide Group first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 9 quarters.
  • C WorldWide Group's Aclaris Therapeutics position peaked at $4.84M in Q2 2018.
  • 84 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2019.

Based on C WorldWide Group's 13F filing for Q2 2019, filed 2 Aug 2019.